Virginia is currently home to 1850 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: Inova Health Care Services, Fairfax, Virginia
Conditions: Merkel Cell Carcinoma
Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination
Recruiting
Currently there are no standards for healthcare worker vaccination with the HPV, Gardasil-9 vaccine. For health care workers, the CDC only recommends for vaccination against hepatitis B, influenza virus, Measles, Mumps and Rubella (MMR), Chickenpox (Varicella), Tetanus, Diptheria, and Pertussis (Tdap), and meninogococcal infections6
Gender:
All
Ages:
Between 27 years and 69 years
Trial Updated:
02/16/2023
Locations: EVMS Otolaryngology, Norfolk, Virginia
Conditions: Papillomavirus Vaccines
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT
Recruiting
Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT The purpose of this study is to collect data on the NVHO device at up to three sites.
Gender:
All
Ages:
All
Trial Updated:
02/15/2023
Locations: The Retina Group of Washington, Fairfax, Virginia
Conditions: Diabetic Macular Edema
Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease
Recruiting
This is a randomized, double-blinded, placebo-controlled, crossover trial that aims to 1) determine the efficacy of THC-free cannabidiol (CBD oil) in reducing the severity of agitation among participants and 2) determine whether THC-free CBD oil can reduce the burden on caregivers and increase the participants' quality of life.
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
02/15/2023
Locations: Eastern Virginia Medical School, Norfolk, Virginia
Conditions: Alzheimer Disease, Dementia, Major Neurocognitive Disorder With Aggressive Behavior
Combination 5-FU / Calcipotriene Cream for SCCIS/SCC
Recruiting
The study will determine if calcipotriene and 5-fluorouracil (5-FU) creams when combined can treat SCCIS and superficially invasive SCC (but not deeply invasive or high-risk cutaneous SCC). 30 Patients will be divided into a 7 day treatment group (n=10), a 14 day treatment group (n=10), and a placebo group (n=10, divided into 7 and 14 days evenly). Following treatment with the topical chemotherapeutic medication, tumors would be completely excised according to standard of care, and specimens wou... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
02/10/2023
Locations: Carilion Clinic Dermatology and Mohs Surgery, Roanoke, Virginia
Conditions: Squamous Cell Carcinoma
Validation of a Salivary miRNA Diagnostic Test for ASD
Recruiting
This study involves sample collection to identify biomarkers relating to Autism Spectrum Disorder(ASD) in the saliva of children who are between the ages of 18 months to 6 years and 11 months. Participants will at each timepoint have a non-invasive saliva swab collected and complete a brief demographic and medical history questionnaire as well. Children in the pediatric/provider setting who will receive a referral for an ASD diagnosis because they were determined to have a suspicion of developin... Read More
Gender:
All
Ages:
Between 18 months and 7 years
Trial Updated:
02/06/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Autism Spectrum Disorder, Developmental Delay
Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C)
Recruiting
This study of the efficacy and safety of Plecanatide in children 6 to <18 Years of Age with Irritable Bowel Syndrome with Constipation (IBS-C)
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
02/06/2023
Locations: Synergy Research Site, Newport News, Virginia
Conditions: Irritable Bowel Syndrome With Constipation
A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer
Recruiting
The objective of this prospective, multi-centre study is to evaluate the performance of ADXBLADDER, a urine MCM5 ELISA test, as an aid in the detection of bladder cancer recurrence. Patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (NMIBC) follow-up will be recruited and asked to provide a urine sample to be tested with ADXBLADDER. To assess the diagnostic accuracy of the test, the MCM5 results will be compared with the gold standard cystoscopy and pathology of r... Read More
Gender:
All
Ages:
22 years and above
Trial Updated:
01/30/2023
Locations: Virginia Urology Center, Richmond, Virginia
Conditions: Bladder Cancer
Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC
Recruiting
The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)
Gender:
Male
Ages:
50 years and above
Trial Updated:
01/23/2023
Locations: Lucid Investigative Site, Richmond, Virginia
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma, Barretts Esophagus With Dysplasia, Barrett's Esophagus Without Dysplasia
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
Recruiting
This is a first-in-human, phase 1, open-label, dose-escalation study of STI-6643 administered by intravenous infusion in subjects with a relapsed/refractory advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Solid Tumor, Relapsed Solid Neoplasm, Refractory Tumor
Heart Failure Monitoring With Eko Electronic Stethoscopes (CardioMEMS)
Recruiting
This study will enroll heart failure (HF) patients who are under active management with an implanted pulmonary artery pressure sensor (CardioMEMS). Subjects will be provided an electronic stethoscope (the Eko DUO) to take at-home heart sound, lung sound, and ECG recordings in conjunction with regimented CardioMEMS measurements. These two datasets will be used to confirm whether an AI/ML model to track HF status can be developed.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/16/2022
Locations: Sentara Cardiovascular Research Institute, Norfolk, Virginia
Conditions: Heart Failure
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
Recruiting
The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.
Gender:
Female
Ages:
Between 40 years and 69 years
Trial Updated:
11/16/2022
Locations: UVA Breast Care Center, Charlottesville, Virginia
Conditions: Mammographic Breast Density, Mammography